James Mark Lin, MD
Gastroenterology · Stanford
- Medicare standing
- Clear
- Enrolled, allowed to bill and order, not excluded
- Plans that list them
- 10
- 2 carriers
- Office
- 1
Offices
1 location · Stanford Health Care · 3,152 clinicians in this group
Hospitals listed: Stanford Health Care · Stanford Health Care Tri-Valley. That is not proof they admit you there this week.
Plans that list them
10 plans · 2 carriers
A missing listing does not mean out of network. Directories change, and a listing does not cover every office. Call Dr. Lin’s office at (650) 723-4000 to confirm they take your plan. Ask about the office you use, its medical group, referrals and appointments.
10 of 10 plans
| Alignment Health BreathEasy (HMO C-SNP) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health Clarity (HMO C-SNP) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health Harmony (HMO) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health Heart & Diabetes (HMO C-SNP) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health Heart & Diabetes CalPlus (HMO C-SNP) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health Heart & Diabetes Care (HMO C-SNP) | Alignment Health Plan | Listed | Sep 28, 2026 |
| Alignment Health Heart & Diabetes Choice (HMO C-SNP) | Alignment Health Plan | Listed | Sep 28, 2026 |
| Alignment Health Honor+ Plan (HMO) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health My Choice CalCare (HMO) | Alignment Health Plan | Listed | Oct 3, 2026 |
| SCAN Strive (HMO C-SNP) | SCAN Health Plan | Listed | Oct 3, 2026 |
California Medical Board record
Licence A102814 · Current
Licensed to practise in California · since 2008 · expires 2027-06-30 · Vanderbilt University School of Medicine.
No disciplinary actions, convictions, malpractice judgments or citations in this record.
Hospitals they work in
2 hospitals
These rate the hospital, not this clinician. Most measures at most hospitals are no different from the national rate.
- Stanford Health CareStanford, CAAcute Care Hospital · Voluntary non-profit - Private · Has an emergency departmentPart of Stanford Health Care, which runs 3 hospitalsHome of Stanford Cancer Institute, a National Cancer Institute designated comprehensive cancer centrePatients rate it 4 of 5 · 83% would definitely recommend itOverall rating: 5 of 5 starsWorse than the national rate — Perioperative pulmonary embolism or deep vein thrombosis rate: 5.31 (4.24 to 6.37) · 8,661 cases, Jul 2022 – Jun 2024Worse than the national rate — Rate of inpatient admissions for patients receiving outpatient chemotherapy: 14.1 (12.7 to 15.7) · 2,191 cases, Jan 2024 – Dec 2024Better than the national rate — Postoperative respiratory failure rate: 4.08 (1.95 to 6.21) · 5,296 cases, Jul 2022 – Jun 2024Better than the national rate — Catheter Associated Urinary Tract Infections (ICU + select Wards): 0.317, Oct 2024 – Sep 2025Better than the national rate — Clostridium Difficile (C.Diff): 0.446, Oct 2024 – Sep 2025Better than the national rate — SSI - Colon Surgery: 0.241, Oct 2024 – Sep 2025Better than the national rate — Ratio of unplanned hospital visits after hospital outpatient surgery: 0.7 (0.6 to 0.9) · 3,348 cases, Jan 2024 – Dec 2024
- Stanford Health Care Tri-ValleyPleasanton, CAAcute Care Hospital · Voluntary non-profit - Private · Has an emergency department · Birthing-friendlyPart of Stanford Health Care, which runs 3 hospitalsPatients rate it 3 of 5 · 74% would definitely recommend itOverall rating: 5 of 5 starsBetter than the national rate — Central Line Associated Bloodstream Infection (ICU + select Wards): 0.178, Oct 2024 – Sep 2025Better than the national rate — Clostridium Difficile (C.Diff): 0.237, Oct 2024 – Sep 2025
See every measure and the patient survey for Stanford Health Care
Behind the star rating — Deaths: 5 better, 3 the same, 0 worse of 8 measures. Safety: 3 better, 5 the same, 0 worse of 8 measures. Readmissions: 2 better, 5 the same, 4 worse of 11 measures. The star rating is worked out from an earlier period than the measures below, so the two can disagree.
| Perioperative pulmonary embolism or deep vein thrombosis rateComplications and deaths | 5.31 (4.24 to 6.37) · 8,661 cases | Worse | Jul 2022 – Jun 2024 |
| Rate of inpatient admissions for patients receiving outpatient chemotherapyUnplanned return visits | 14.1 (12.7 to 15.7) · 2,191 cases | Worse | Jan 2024 – Dec 2024 |
| Postoperative respiratory failure rateComplications and deaths | 4.08 (1.95 to 6.21) · 5,296 cases | Better | Jul 2022 – Jun 2024 |
| Catheter Associated Urinary Tract Infections (ICU + select Wards)Infections | 0.317 | Better | Oct 2024 – Sep 2025 |
| Clostridium Difficile (C.Diff)Infections | 0.446 | Better | Oct 2024 – Sep 2025 |
| SSI - Colon SurgeryInfections | 0.241 | Better | Oct 2024 – Sep 2025 |
| Ratio of unplanned hospital visits after hospital outpatient surgeryUnplanned return visits | 0.7 (0.6 to 0.9) · 3,348 cases | Better | Jan 2024 – Dec 2024 |
| Abdominopelvic accidental puncture or laceration rateComplications and deaths | 1.06 (0.45 to 1.67) · 5,374 cases | No different | Jul 2022 – Jun 2024 |
| CMS Medicare PSI 90: Patient safety and adverse events compositeComplications and deaths | 0.86 (0.72 to 1) | No different | Jul 2022 – Jun 2024 |
| Death rate among surgical inpatients with serious treatable complicationsComplications and deaths | 166.09 (137.88 to 194.3) · 470 cases | No different | Jul 2022 – Jun 2024 |
| Death rate for CABG surgery patientsComplications and deaths | 1.1 · 192 cases | None | Jul 2022 – Jun 2025 |
| Death rate for COPD patientsComplications and deaths | 6.4 · 146 cases | None | Jul 2022 – Jun 2025 |
| Death rate for heart attack patientsComplications and deaths | 9.7 · 253 cases | None | Jul 2022 – Jun 2025 |
| Death rate for heart failure patientsComplications and deaths | 6.3 · 880 cases | None | Jul 2022 – Jun 2025 |
| Death rate for pneumonia patientsComplications and deaths | 10.3 · 935 cases | None | Jul 2022 – Jun 2025 |
| Death rate for stroke patientsComplications and deaths | 8.7 · 501 cases | None | Jul 2023 – Jun 2025 |
| Hybrid Hospital-Wide All-Cause Risk Standardized Mortality RateComplications and deaths | 2.1 · 7,730 cases | None | Jul 2024 – Jun 2025 |
| Iatrogenic pneumothorax rateComplications and deaths | 0.13 (0 to 0.27) · 20,799 cases | No different | Jul 2022 – Jun 2024 |
| In-hospital fall-associated fracture rateComplications and deaths | 0.28 (0.14 to 0.43) · 23,182 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative acute kidney injury requiring dialysis rateComplications and deaths | 0.94 (0.2 to 1.68) · 5,694 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative hemorrhage or hematoma rateComplications and deaths | 2.36 (1.54 to 3.19) · 7,846 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative sepsis rateComplications and deaths | 5.2 (3.76 to 6.64) · 5,603 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative wound dehiscence rateComplications and deaths | 1.38 (0.23 to 2.53) · 2,211 cases | No different | Jul 2022 – Jun 2024 |
| Pressure ulcer rateComplications and deaths | 0.52 (0.21 to 0.83) · 19,915 cases | No different | Jul 2022 – Jun 2024 |
| Rate of complications for hip/knee replacement patientsComplications and deaths | 3.6 · 416 cases | None | Apr 2023 – Mar 2025 |
| Central Line Associated Bloodstream Infection (ICU + select Wards)Infections | 0.869 | No different | Oct 2024 – Sep 2025 |
| MRSA BacteremiaInfections | 0.857 | No different | Oct 2024 – Sep 2025 |
| SSI - Abdominal HysterectomyInfections | 0.368 | No different | Oct 2024 – Sep 2025 |
| Acute Myocardial Infarction (AMI) 30-Day Readmission RateUnplanned return visits | 16.2 · 247 cases | None | Jul 2023 – Jun 2025 |
| Heart failure (HF) 30-Day Readmission RateUnplanned return visits | 20.5 · 1,021 cases | None | Jul 2023 – Jun 2025 |
| Hospital return days for heart attack patientsUnplanned return visits | 47.8 · 258 cases | None | Jul 2022 – Jun 2025 |
| Hospital return days for heart failure patientsUnplanned return visits | -1.6 · 990 cases | None | Jul 2022 – Jun 2025 |
| Hospital return days for pneumonia patientsUnplanned return visits | 20.8 · 976 cases | None | Jul 2022 – Jun 2025 |
| Pneumonia (PN) 30-Day Readmission RateUnplanned return visits | 16.5 · 959 cases | None | Jul 2023 – Jun 2025 |
| Rate of emergency department (ED) visits for patients receiving outpatient chemotherapyUnplanned return visits | 5.2 (4.4 to 6.2) · 2,191 cases | No different | Jan 2024 – Dec 2024 |
| Rate of readmission after hip/knee replacementUnplanned return visits | 5.1 · 425 cases | None | Jul 2023 – Jun 2025 |
| Rate of readmission for CABGUnplanned return visits | 9.6 · 158 cases | None | Jul 2023 – Jun 2025 |
| Rate of readmission for chronic obstructive pulmonary disease (COPD) patientsUnplanned return visits | 19.6 · 183 cases | None | Jul 2023 – Jun 2025 |
| Rate of unplanned hospital visits after colonoscopy (per 1,000 colonoscopies)Unplanned return visits | 12.7 (10.4 to 15.4) · 4,578 cases | No different | Jan 2022 – Dec 2024 |
What patients said (6,810 patients answered, 25% of those asked)
| Cleanliness | 4 |
| Nurse communication | 4 |
| Doctor communication | 4 |
| Communication about medicines | 3 |
| Discharge information | 4 |
| Overall hospital rating | 4 |
| Quietness | 2 |
| Recommend hospital | 5 |
| Room was "always" clean | 75% |
| Nurses "always" communicated well | 82% |
| Doctors "always" communicated well | 81% |
| Staff "always" explained | 63% |
| Yes, staff "did" give patients this information | 89% |
| Yes, staff "did" give patients information about help after discharge | 89% |
| Doctors "always" explained things so they could understand | 76% |
| Doctors "always" listened carefully | 80% |
| Doctors "always" treated them with courtesy and respect | 87% |
| Patients who gave a rating of "9" or "10" (high) | 79% |
| Staff "always" explained new medications | 76% |
| Nurses "always" explained things so they could understand | 77% |
| Nurses "always" listened carefully | 79% |
| Nurses "always" treated them with courtesy and respect | 88% |
| "Always" quiet at night | 53% |
| "YES", patients would definitely recommend the hospital | 83% |
| Staff "always" explained possible side effects | 50% |
| Yes, staff "did" give patients information about possible symptoms | 90% |
See every measure and the patient survey for Stanford Health Care Tri-Valley
Behind the star rating — Deaths: 2 better, 6 the same, 0 worse of 8 measures. Safety: 2 better, 5 the same, 0 worse of 7 measures. Readmissions: 2 better, 7 the same, 0 worse of 9 measures. The star rating is worked out from an earlier period than the measures below, so the two can disagree.
| Central Line Associated Bloodstream Infection (ICU + select Wards)Infections | 0.178 | Better | Oct 2024 – Sep 2025 |
| Clostridium Difficile (C.Diff)Infections | 0.237 | Better | Oct 2024 – Sep 2025 |
| Abdominopelvic accidental puncture or laceration rateComplications and deaths | 0.79 (0 to 1.73) · 1,041 cases | No different | Jul 2022 – Jun 2024 |
| CMS Medicare PSI 90: Patient safety and adverse events compositeComplications and deaths | 0.79 (0.5 to 1.08) | No different | Jul 2022 – Jun 2024 |
| Death rate among surgical inpatients with serious treatable complicationsComplications and deaths | 145.81 (96.5 to 195.12) · 72 cases | No different | Jul 2022 – Jun 2024 |
| Death rate for CABG surgery patientsComplications and deaths | 2.9 · 55 cases | None | Jul 2022 – Jun 2025 |
| Death rate for COPD patientsComplications and deaths | 8.6 · 92 cases | None | Jul 2022 – Jun 2025 |
| Death rate for heart attack patientsComplications and deaths | 12.5 · 96 cases | None | Jul 2022 – Jun 2025 |
| Death rate for heart failure patientsComplications and deaths | 9.5 · 395 cases | None | Jul 2022 – Jun 2025 |
| Death rate for pneumonia patientsComplications and deaths | 10.3 · 391 cases | None | Jul 2022 – Jun 2025 |
| Death rate for stroke patientsComplications and deaths | 10.1 · 162 cases | None | Jul 2023 – Jun 2025 |
| Hybrid Hospital-Wide All-Cause Risk Standardized Mortality RateComplications and deaths | 3 · 1,736 cases | None | Jul 2024 – Jun 2025 |
| Iatrogenic pneumothorax rateComplications and deaths | 0.16 (0 to 0.37) · 4,425 cases | No different | Jul 2022 – Jun 2024 |
| In-hospital fall-associated fracture rateComplications and deaths | 0.22 (0.02 to 0.41) · 4,771 cases | No different | Jul 2022 – Jun 2024 |
| Perioperative pulmonary embolism or deep vein thrombosis rateComplications and deaths | 3.45 (1.46 to 5.44) · 1,403 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative acute kidney injury requiring dialysis rateComplications and deaths | 1.5 (0.05 to 2.94) · 645 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative hemorrhage or hematoma rateComplications and deaths | 1.81 (0.38 to 3.24) · 1,279 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative respiratory failure rateComplications and deaths | 8.53 (3.2 to 13.85) · 639 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative sepsis rateComplications and deaths | 5.15 (1.89 to 8.41) · 648 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative wound dehiscence rateComplications and deaths | 1.61 (0.14 to 3.07) · 370 cases | No different | Jul 2022 – Jun 2024 |
| Pressure ulcer rateComplications and deaths | 0.16 (0 to 0.83) · 4,160 cases | No different | Jul 2022 – Jun 2024 |
| Rate of complications for hip/knee replacement patientsComplications and deaths | 4 · 74 cases | None | Apr 2023 – Mar 2025 |
| Catheter Associated Urinary Tract Infections (ICU + select Wards)Infections | 0.369 | No different | Oct 2024 – Sep 2025 |
| MRSA BacteremiaInfections | 1.112 | No different | Oct 2024 – Sep 2025 |
| SSI - Colon SurgeryInfections | 0 | No different | Oct 2024 – Sep 2025 |
| Acute Myocardial Infarction (AMI) 30-Day Readmission RateUnplanned return visits | 13.1 · 110 cases | None | Jul 2023 – Jun 2025 |
| Heart failure (HF) 30-Day Readmission RateUnplanned return visits | 20.1 · 437 cases | None | Jul 2023 – Jun 2025 |
| Hospital return days for heart attack patientsUnplanned return visits | -5.8 · 94 cases | None | Jul 2022 – Jun 2025 |
| Hospital return days for heart failure patientsUnplanned return visits | -19.3 · 456 cases | None | Jul 2022 – Jun 2025 |
| Hospital return days for pneumonia patientsUnplanned return visits | -0.3 · 402 cases | None | Jul 2022 – Jun 2025 |
| Pneumonia (PN) 30-Day Readmission RateUnplanned return visits | 15.8 · 358 cases | None | Jul 2023 – Jun 2025 |
| Rate of emergency department (ED) visits for patients receiving outpatient chemotherapyUnplanned return visits | 6.8 (4.7 to 9.6) · 198 cases | No different | Jan 2024 – Dec 2024 |
| Rate of inpatient admissions for patients receiving outpatient chemotherapyUnplanned return visits | 10.1 (7.5 to 13.6) · 198 cases | No different | Jan 2024 – Dec 2024 |
| Rate of readmission after hip/knee replacementUnplanned return visits | 5.3 · 80 cases | None | Jul 2023 – Jun 2025 |
| Rate of readmission for CABGUnplanned return visits | 10.9 · 46 cases | None | Jul 2023 – Jun 2025 |
| Rate of readmission for chronic obstructive pulmonary disease (COPD) patientsUnplanned return visits | 19.3 · 92 cases | None | Jul 2023 – Jun 2025 |
| Rate of unplanned hospital visits after colonoscopy (per 1,000 colonoscopies)Unplanned return visits | 12.4 (9.6 to 16.2) · 1,532 cases | No different | Jan 2022 – Dec 2024 |
| Ratio of unplanned hospital visits after hospital outpatient surgeryUnplanned return visits | 1 (0.8 to 1.2) · 929 cases | No different | Jan 2024 – Dec 2024 |
What patients said (1,268 patients answered, 26% of those asked)
| Cleanliness | 3 |
| Nurse communication | 3 |
| Doctor communication | 4 |
| Communication about medicines | 3 |
| Discharge information | 4 |
| Overall hospital rating | 3 |
| Quietness | 2 |
| Recommend hospital | 4 |
| Room was "always" clean | 65% |
| Nurses "always" communicated well | 77% |
| Doctors "always" communicated well | 79% |
| Staff "always" explained | 58% |
| Yes, staff "did" give patients this information | 88% |
| Yes, staff "did" give patients information about help after discharge | 88% |
| Doctors "always" explained things so they could understand | 74% |
| Doctors "always" listened carefully | 78% |
| Doctors "always" treated them with courtesy and respect | 86% |
| Patients who gave a rating of "9" or "10" (high) | 70% |
| Staff "always" explained new medications | 72% |
| Nurses "always" explained things so they could understand | 73% |
| Nurses "always" listened carefully | 74% |
| Nurses "always" treated them with courtesy and respect | 84% |
| "Always" quiet at night | 42% |
| "YES", patients would definitely recommend the hospital | 74% |
| Staff "always" explained possible side effects | 44% |
| Yes, staff "did" give patients information about possible symptoms | 89% |
Original Medicare doctor bills
$154,283
Medicare paid this office $154,283 for 590 people.
This is what Medicare paid the clinician — not Medicare Advantage, and not the pharmacy.
| Return visit (30+ min) | 197 | $33,496 | $115 |
| New patient visit (45+ min) | 155 | $20,994 | $135 |
| Long return visit (40+ min) | 92 | $16,227 | $161 |
| Removal of polyps or growths of large bowel using an endoscope with mechanical snare | 67 | $15,615 | $233 |
| Biopsy of large bowel using a flexible endoscope | 115 | $13,781 | $120 |
See all 15 services
| Return visit (30+ min) | 197 | $33,496 | $115 |
| New patient visit (45+ min) | 155 | $20,994 | $135 |
| Long return visit (40+ min) | 92 | $16,227 | $161 |
| Removal of polyps or growths of large bowel using an endoscope with mechanical snare | 67 | $15,615 | $233 |
| Biopsy of large bowel using a flexible endoscope | 115 | $13,781 | $120 |
| Biopsy of esophagus, stomach, and/or upper small bowel using a flexible endoscope | 142 | $10,298 | $72 |
| New patient visit (60+ min) | 45 | $8,840 | $196 |
| Colorectal cancer screening; colonoscopy on individual not meeting criteria for high risk | 31 | $6,307 | $203 |
| Colorectal cancer screening; colonoscopy on individual at high risk | 24 | $4,784 | $199 |
| Short return visit (20+ min) | 54 | $4,572 | $82 |
| Balloon dilation of esophagus, stomach, and/or upper small bowel using a flexible endoscope, less than 3.0 cm | 29 | $3,381 | $113 |
| Initial hospital care with moderate level of medical decision making at least 75 minutes | 21 | $3,367 | $153 |
| New patient visit (30+ min) | 25 | $2,091 | $84 |
| Subsequent hospital care with moderate levelof medical decision making at least 35 minutes | 21 | $1,812 | $67 |
| Visit complexity inherent to evaluation and management associated with medical care services that serve as the continuing focal point for all needed health care services and/or with medical care services that are part of ongoing care related to a patient's | 44 | $651 | $15 |
Procedures Medicare counted
| Colonoscopy | 85 | More than 76% of doctors who do this |
| Upper gastrointestinal (GI) endoscopy for acid reflux | 189 | More than 89% of doctors who do this |
Who their Medicare patients are
590 Original Medicare patients in 2024. Average age 74 · Under 65 8% · 85 and older 12% · Women 55% · Also on Medicaid 22% · Health risk score 1.40. At or below the middle of the specialty; the typical gastroenterology clinician is at 1.42.
Conditions among them: High blood pressure 73% · Chronic kidney disease 33% · Diabetes 31% · Coronary heart disease 29% · Cancer 22% · Atrial fibrillation 21% · Depression 21% · Heart failure 18% · COPD 15% · Stroke 7% · Dementia 6%.
The office billed $1,402,240, Medicare allowed $198,764 and paid $154,283; for 1,232 services of 32 kinds.
Original Medicare patients only. A risk score of 1.0 is the average Medicare patient; higher means sicker. Any count under 11 is hidden.
Year by year
| 2024 | 590 | 1,232 | 74 | 1.40 | $1,402,240 | $154,283 |
| 2023 | 517 | 1,035 | 74 | 1.45 | $1,073,950 | $129,062 |
| 2022 | 502 | 1,133 | 74 | 1.48 | $1,206,557 | $137,670 |
| 2021 | 532 | 1,423 | 73 | 1.47 | $1,409,129 | $173,078 |
| 2020 | 397 | 1,177 | 74 | 1.69 | $1,083,203 | $126,432 |
| 2019 | 474 | 1,439 | 74 | 1.50 | $1,220,046 | $143,385 |
| 2018 | 439 | 1,303 | 74 | 1.51 | $977,824 | $131,153 |
| 2017 | 456 | 1,318 | 74 | 1.66 | $898,375 | $130,541 |
| 2016 | 510 | 1,440 | 75 | 1.65 | $884,814 | $138,741 |
| 2015 | 485 | 1,521 | 74 | 1.57 | $793,337 | $146,654 |
| 2014 | 444 | 1,638 | 74 | 1.82 | $626,461 | $145,835 |
| 2013 | 452 | 1,517 | 74 | 1.71 | $558,629 | $141,964 |
Original Medicare only. A service billed for fewer than 11 people in a year is hidden, so the lines can add up to less than the year's total.
See the services billed each year
2023: 15 services
| Return visit (30+ min) | 157 | $25,730 | $112 |
| Long return visit (40+ min) | 97 | $15,375 | $157 |
| New patient visit (45+ min) | 105 | $14,530 | $138 |
| Removal of polyps or growths of large bowel using an endoscope with mechanical snare | 54 | $11,604 | $215 |
| Biopsy of large bowel using a flexible endoscope | 82 | $9,584 | $117 |
| Biopsy of esophagus, stomach, and/or upper small bowel using a flexible endoscope | 94 | $6,487 | $68 |
| Colorectal cancer screening; colonoscopy on individual not meeting criteria for high risk | 31 | $6,293 | $203 |
| Initial hospital care with moderate level of medical decision making at least 75 minutes | 38 | $5,688 | $150 |
| New patient visit (60+ min) | 26 | $5,108 | $196 |
| Colorectal cancer screening; colonoscopy on individual at high risk | 23 | $4,513 | $196 |
| Subsequent hospital care with moderate levelof medical decision making at least 35 minutes | 36 | $3,928 | $70 |
| Short return visit (20+ min) | 44 | $3,868 | $76 |
| Balloon dilation of esophagus, stomach, and/or upper small bowel using a flexible endoscope, less than 3.0 cm | 19 | $2,170 | $109 |
| New patient visit (30+ min) | 19 | $1,707 | $90 |
| Telehealth originating site facility fee | 33 | $808 | $22 |
2022: 18 services
| Return visit (30+ min) | 174 | $25,744 | $109 |
| New patient visit (45+ min) | 124 | $18,021 | $145 |
| Removal of polyps or growths of large bowel using an endoscope with mechanical snare | 68 | $15,009 | $218 |
| Long return visit (40+ min) | 76 | $13,121 | $164 |
| Biopsy of large bowel using a flexible endoscope | 121 | $12,480 | $102 |
| Biopsy of esophagus, stomach, and/or upper small bowel using a flexible endoscope | 132 | $10,144 | $76 |
| Initial hospital care with moderate level of medical decision making at least 75 minutes | 43 | $7,831 | $174 |
| Colorectal cancer screening; colonoscopy on individual not meeting criteria for high risk | 25 | $5,145 | $206 |
| Short return visit (20+ min) | 52 | $4,919 | $79 |
| Colorectal cancer screening; colonoscopy on individual at high risk | 21 | $4,163 | $198 |
| Subsequent hospital care with moderate levelof medical decision making at least 35 minutes | 37 | $3,646 | $63 |
| New patient visit (60+ min) | 16 | $3,342 | $209 |
| New patient visit (30+ min) | 28 | $2,867 | $102 |
| Diagnostic exam of large bowel using a flexible endoscope | 15 | $2,209 | $147 |
| Balloon dilation of esophagus, stomach, and/or upper small bowel using a flexible endoscope, less than 3.0 cm | 16 | $1,768 | $110 |
| Telephone medical discussion with physician, 21-30 minutes | 11 | $1,296 | $108 |
| New patient visit (15+ min) | 11 | $551 | $50 |
| Moderate sedation services provided by the same physician or other qualified health care professional performing a gastrointestinal endoscopic service that sedation supports, requiring the presence of an independent trained observer to assist in the monito | 12 | $61 | $5 |
2021: 18 services
| Return visit (30+ min) | 179 | $30,039 | $120 |
| New patient visit (45+ min) | 144 | $22,423 | $156 |
| Removal of polyps or growths of large bowel using an endoscope with mechanical snare | 77 | $17,624 | $226 |
| Biopsy of large bowel using a flexible endoscope | 116 | $13,332 | $112 |
| Biopsy of esophagus, stomach, and/or upper small bowel using a flexible endoscope | 174 | $13,144 | $74 |
| Initial hospital care with moderate level of medical decision making at least 75 minutes | 60 | $11,561 | $181 |
| Long return visit (40+ min) | 50 | $9,616 | $172 |
| Colorectal cancer screening; colonoscopy on individual not meeting criteria for high risk | 37 | $7,706 | $208 |
| New patient visit (60+ min) | 34 | $7,473 | $220 |
| Subsequent hospital care with moderate levelof medical decision making at least 35 minutes | 55 | $6,347 | $64 |
| Telephone medical discussion with physician, 21-30 minutes | 43 | $5,925 | $116 |
| Short return visit (20+ min) | 59 | $5,450 | $81 |
| Colorectal cancer screening; colonoscopy on individual at high risk | 22 | $4,673 | $212 |
| New patient visit (30+ min) | 39 | $3,895 | $100 |
| Balloon dilation of esophagus, stomach, and/or upper small bowel using a flexible endoscope, less than 3.0 cm | 16 | $1,843 | $115 |
| Imaging of digestive tract done from the inside of the digestive tract | 11 | $1,304 | $119 |
| New patient visit (15+ min) | 12 | $497 | $41 |
| Moderate sedation services provided by the same physician or other qualified health care professional performing a gastrointestinal endoscopic service that sedation supports, requiring the presence of an independent trained observer to assist in the monito | 69 | $322 | $5 |
2020: 16 services
| Return visit (30+ min) | 146 | $21,174 | $98 |
| Biopsy of large bowel using a flexible endoscope | 80 | $11,355 | $138 |
| New patient visit (45+ min) | 67 | $10,763 | $161 |
| Initial hospital care with moderate level of medical decision making at least 75 minutes | 50 | $10,077 | $180 |
| Long return visit (40+ min) | 62 | $9,483 | $146 |
| Removal of polyps or growths of large bowel using an endoscope with mechanical snare | 38 | $8,657 | $222 |
| Subsequent hospital care with moderate levelof medical decision making at least 35 minutes | 47 | $8,308 | $66 |
| Telephone medical discussion with physician, 21-30 minutes | 57 | $8,141 | $107 |
| Biopsy of esophagus, stomach, and/or upper small bowel using a flexible endoscope | 106 | $7,593 | $70 |
| Short return visit (20+ min) | 53 | $4,362 | $66 |
| New patient visit (60+ min) | 17 | $3,744 | $220 |
| Colorectal cancer screening; colonoscopy on individual at high risk | 16 | $3,463 | $216 |
| Colorectal cancer screening; colonoscopy on individual not meeting criteria for high risk | 14 | $2,922 | $209 |
| New patient visit (30+ min) | 19 | $2,314 | $122 |
| Balloon dilation of esophagus, stomach, and/or upper small bowel using a flexible endoscope, less than 3.0 cm | 18 | $2,061 | $108 |
| Moderate sedation services provided by the same physician or other qualified health care professional performing a gastrointestinal endoscopic service that sedation supports, requiring the presence of an independent trained observer to assist in the monito | 90 | $444 | $5 |
2019: 18 services
| Return visit (30+ min) | 189 | $29,997 | $95 |
| Removal of polyps or growths of large bowel using an endoscope with mechanical snare | 58 | $12,945 | $216 |
| Subsequent hospital care with moderate levelof medical decision making at least 35 minutes | 65 | $10,976 | $65 |
| New patient visit (45+ min) | 79 | $10,975 | $139 |
| Biopsy of esophagus, stomach, and/or upper small bowel using a flexible endoscope | 131 | $10,623 | $79 |
| Biopsy of large bowel using a flexible endoscope | 89 | $10,146 | $114 |
| Long return visit (40+ min) | 74 | $8,994 | $118 |
| Initial hospital care with moderate level of medical decision making at least 75 minutes | 47 | $8,854 | $181 |
| Colorectal cancer screening; colonoscopy on individual at high risk | 32 | $6,832 | $213 |
| Short return visit (20+ min) | 91 | $6,525 | $65 |
| New patient visit (60+ min) | 28 | $5,060 | $181 |
| Colorectal cancer screening; colonoscopy on individual not meeting criteria for high risk | 21 | $4,486 | $214 |
| Balloon dilation of esophagus, stomach, and/or upper small bowel using a flexible endoscope, less than 3.0 cm | 17 | $2,138 | $119 |
| New patient visit (15+ min) | 33 | $2,119 | $64 |
| New patient visit (30+ min) | 23 | $1,871 | $81 |
| Follow-up observation care per day, typically 35 minutes | 11 | $1,611 | $95 |
| Initial hospital care with straightforward or low-level medical decision making at least 55 minutes | 12 | $1,436 | $120 |
| Moderate sedation services provided by the same physician or other qualified health care professional performing a gastrointestinal endoscopic service that sedation supports, requiring the presence of an independent trained observer to assist in the monito | 117 | $569 | $5 |
2018: 21 services
| Return visit (30+ min) | 185 | $26,835 | $96 |
| Long return visit (40+ min) | 89 | $11,024 | $115 |
| Subsequent hospital care with moderate levelof medical decision making at least 35 minutes | 66 | $9,637 | $65 |
| New patient visit (45+ min) | 57 | $8,426 | $148 |
| Removal of polyps or growths of large bowel using an endoscope with mechanical snare | 32 | $7,293 | $228 |
| Biopsy of esophagus, stomach, and/or upper small bowel using a flexible endoscope | 71 | $6,357 | $86 |
| New patient visit (60+ min) | 34 | $6,187 | $182 |
| Initial hospital care with straightforward or low-level medical decision making at least 55 minutes | 48 | $5,927 | $121 |
| Biopsy of large bowel using a flexible endoscope | 47 | $5,768 | $123 |
| Short return visit (20+ min) | 70 | $4,856 | $65 |
| Removal of polyps or growths of large bowel using an endoscope with mechanical snare | 20 | $4,638 | $232 |
| Colorectal cancer screening; colonoscopy on individual not meeting criteria for high risk | 20 | $4,106 | $205 |
| Initial hospital care with moderate level of medical decision making at least 75 minutes | 22 | $3,961 | $180 |
| Colorectal cancer screening; colonoscopy on individual at high risk | 18 | $3,787 | $210 |
| Biopsy of large bowel using a flexible endoscope | 30 | $3,488 | $116 |
| Biopsy of esophagus, stomach, and/or upper small bowel using a flexible endoscope | 33 | $2,824 | $86 |
| New patient visit (30+ min) | 27 | $2,346 | $87 |
| New patient visit (15+ min) | 31 | $2,004 | $65 |
| Balloon dilation of esophagus, stomach, and/or upper small bowel using a flexible endoscope, less than 3.0 cm | 14 | $1,686 | $120 |
| Moderate sedation services provided by the same physician or other qualified health care professional performing a gastrointestinal endoscopic service that sedation supports, requiring the presence of an independent trained observer to assist in the monito | 87 | $409 | $5 |
| Moderate sedation services provided by the same physician or other qualified health care professional performing a gastrointestinal endoscopic service that sedation supports, requiring the presence of an independent trained observer to assist in the monito | 39 | $172 | $4 |
2017: 15 services
| Return visit (30+ min) | 209 | $34,205 | $92 |
| Subsequent hospital care with moderate levelof medical decision making at least 35 minutes | 94 | $13,536 | $63 |
| New patient visit (45+ min) | 85 | $11,931 | $140 |
| Initial hospital care with straightforward or low-level medical decision making at least 55 minutes | 95 | $11,478 | $117 |
| Removal of polyps or growths of large bowel using an endoscope with mechanical snare | 46 | $10,385 | $226 |
| Biopsy of large bowel using a flexible endoscope | 81 | $9,968 | $123 |
| Biopsy of esophagus, stomach, and/or upper small bowel using a flexible endoscope | 109 | $9,456 | $86 |
| Colorectal cancer screening; colonoscopy on individual not meeting criteria for high risk | 30 | $5,708 | $190 |
| Colorectal cancer screening; colonoscopy on individual at high risk | 16 | $3,212 | $201 |
| Short return visit (20+ min) | 45 | $2,935 | $61 |
| Biopsy of esophagus, stomach, and/or upper small bowel using a flexible endoscope | 30 | $2,875 | $96 |
| New patient visit (60+ min) | 15 | $2,776 | $185 |
| New patient visit (30+ min) | 26 | $2,388 | $92 |
| Moderate sedation services provided by the same physician or other qualified health care professional performing a gastrointestinal endoscopic service that sedation supports, requiring the presence of an independent trained observer to assist in the monito | 56 | $279 | $5 |
| Moderate sedation services provided by the same physician or other qualified health care professional performing a gastrointestinal endoscopic service that sedation supports, requiring the presence of an independent trained observer to assist in the monito | 13 | $61 | $5 |
2016: 14 services
| Return visit (30+ min) | 226 | $31,925 | $90 |
| Subsequent hospital care with moderate levelof medical decision making at least 35 minutes | 107 | $20,127 | $62 |
| Initial hospital care with straightforward or low-level medical decision making at least 55 minutes | 105 | $14,329 | $116 |
| New patient visit (45+ min) | 85 | $11,356 | $134 |
| Biopsy of large bowel using a flexible endoscope | 76 | $9,676 | $127 |
| Biopsy of esophagus, stomach, and/or upper small bowel using a flexible endoscope | 100 | $9,208 | $89 |
| Removal of polyps or growths of large bowel using an endoscope with mechanical snare | 37 | $8,318 | $225 |
| Short return visit (20+ min) | 109 | $6,819 | $55 |
| Colorectal cancer screening; colonoscopy on individual not meeting criteria for high risk | 29 | $5,767 | $199 |
| Colorectal cancer screening; colonoscopy on individual at high risk | 15 | $2,986 | $199 |
| Biopsy of esophagus, stomach, and/or upper small bowel using a flexible endoscope | 25 | $2,604 | $104 |
| New patient visit (30+ min) | 29 | $2,530 | $87 |
| New patient visit (15+ min) | 18 | $939 | $52 |
| Subsequent hospital care with straightforward or low level of medical decision making, per day at least 25 minutes | 11 | $471 | $34 |
2015: 14 services
| Return visit (30+ min) | 210 | $32,813 | $88 |
| Subsequent hospital care with moderate levelof medical decision making at least 35 minutes | 105 | $21,602 | $62 |
| Removal of polyps or growths of large bowel using an endoscope with mechanical snare | 51 | $13,509 | $260 |
| Biopsy of large bowel using a flexible endoscope | 77 | $11,161 | $143 |
| Initial hospital care with straightforward or low-level medical decision making at least 55 minutes | 88 | $10,837 | $115 |
| Biopsy of esophagus, stomach, and/or upper small bowel using a flexible endoscope | 102 | $10,183 | $98 |
| Short return visit (20+ min) | 118 | $9,329 | $59 |
| New patient visit (45+ min) | 70 | $9,234 | $132 |
| Colorectal cancer screening; colonoscopy on individual not meeting criteria for high risk | 16 | $3,396 | $212 |
| New patient visit (30+ min) | 37 | $3,077 | $83 |
| New patient visit (15+ min) | 36 | $1,719 | $48 |
| Biopsy of large bowel using a flexible endoscope | 13 | $1,407 | $108 |
| Biopsy of esophagus, stomach, and/or upper small bowel using a flexible endoscope | 13 | $1,186 | $91 |
| Subsequent hospital care with straightforward or low level of medical decision making, per day at least 25 minutes | 16 | $839 | $34 |
2014: 13 services
| Return visit (30+ min) | 193 | $28,478 | $88 |
| Subsequent hospital care with moderate levelof medical decision making at least 35 minutes | 148 | $25,479 | $62 |
| Initial hospital care with straightforward or low-level medical decision making at least 55 minutes | 108 | $13,999 | $118 |
| Removal of polyps or growths of large bowel using an endoscope with mechanical snare | 51 | $13,463 | $264 |
| Short return visit (20+ min) | 152 | $13,150 | $59 |
| Biopsy of large bowel using a flexible endoscope | 82 | $11,426 | $138 |
| Biopsy of esophagus, stomach, and/or upper small bowel using a flexible endoscope | 106 | $10,139 | $93 |
| New patient visit (45+ min) | 67 | $8,845 | $132 |
| New patient visit (30+ min) | 37 | $3,259 | $88 |
| Diagnostic exam of large bowel using a flexible endoscope | 14 | $2,632 | $175 |
| Dilation of stomach outlet using a flexible endoscope | 12 | $1,828 | $131 |
| Subsequent hospital care with straightforward or low level of medical decision making, per day at least 25 minutes | 20 | $1,376 | $34 |
| Diagnostic exam of esophagus, stomach, and/or upper small bowel using a flexible endoscope | 11 | $1,089 | $99 |
2013: 12 services
| Subsequent hospital care with moderate levelof medical decision making at least 35 minutes | 156 | $30,251 | $60 |
| Return visit (30+ min) | 174 | $25,852 | $89 |
| Biopsy of large bowel using a flexible endoscope | 81 | $13,665 | $163 |
| New patient visit (45+ min) | 103 | $13,063 | $127 |
| Initial hospital care with straightforward or low-level medical decision making at least 55 minutes | 98 | $12,242 | $112 |
| Biopsy of esophagus, stomach, and/or upper small bowel using a flexible endoscope | 87 | $9,745 | $107 |
| Short return visit (20+ min) | 102 | $8,218 | $64 |
| Removal of polyps or growths of large bowel using an endoscope with mechanical snare | 31 | $8,114 | $262 |
| Colorectal cancer screening; colonoscopy on individual not meeting criteria for high risk | 28 | $4,704 | $168 |
| New patient visit (30+ min) | 39 | $3,528 | $90 |
| Diagnostic exam of large bowel using a flexible endoscope | 14 | $2,602 | $186 |
| New patient visit (15+ min) | 22 | $1,176 | $53 |
Medicaid work
$425 in 2021
Medicaid paid $425 for 12 billed services this clinician did in 2021, up to 12 people in a month for one service.
Medicaid and CHIP claims where this clinician did the service, fee-for-service and managed care together. Any month with fewer than 11 patients is hidden, so small Medicaid practices undercount.
| TISSUE EXAM BY PATHOLOGIST | 12 | $425 |
| 2021 | 12 | 1 | 12 | $425 |
Drugs they prescribed that Part D paid
$880,694
Pharmacies billed $880,694 in 2024.
This is pharmacy cost, not the office bill, and not what patients paid.
Opioids were 0% of their Part D prescriptions (0 of 1,974) in 2024. At or below the middle of the specialty; the typical gastroenterology clinician is at 0%.
1,478 generic and 496 brand-name prescriptions · $880,694 in drug cost · 160 antibiotic prescriptions to 75 people.
Part D prescriptions only. The opioid rate is opioid prescriptions as a share of all this clinician's Part D prescriptions; surgeons and pain specialists run higher than others, so it is shown against the same specialty.
| Creon | 54 | $138,158 | $2,558 |
| Linzess | 96 | $133,171 | $1,387 |
| Xifaxan | 47 | $120,284 | $2,559 |
| Humira(Cf) | 13 | $88,550 | $6,812 |
| Humira | 12 | $81,738 | $6,812 |
See all 30 drugs
| Creon | 54 | $138,158 | $2,558 |
| Linzess | 96 | $133,171 | $1,387 |
| Xifaxan | 47 | $120,284 | $2,559 |
| Humira(Cf) | 13 | $88,550 | $6,812 |
| Humira | 12 | $81,738 | $6,812 |
| Zenpep | 12 | $51,215 | $4,268 |
| Motegrity | 24 | $25,293 | $1,054 |
| Trulance | 14 | $19,252 | $1,375 |
| Sod Sulf-Potass Sulf-Mag Sulf | 238 | $15,419 | $65 |
| Dexlansoprazole Dr | 29 | $12,391 | $427 |
| Colesevelam | 99 | $12,332 | $125 |
| Dexilant | 22 | $11,318 | $514 |
| Pantoprazole | 576 | $10,285 | $18 |
| Mesalamine | 25 | $8,747 | $350 |
| Lubiprostone | 44 | $6,561 | $149 |
| Sucralfate | 78 | $5,333 | $68 |
| Dicyclomine | 56 | $1,883 | $34 |
| Vancomycin | 16 | $1,112 | $69 |
| Nortriptyline | 36 | $721 | $20 |
| Omeprazole | 69 | $611 | $9 |
| Neomycin Sulfate | 26 | $548 | $21 |
| Famotidine | 34 | $476 | $14 |
| Diphenoxylate-Atropine | 11 | $382 | $35 |
| Hydrocortisone | 28 | $241 | $9 |
| Ondansetron | 23 | $211 | $9 |
| Gavilyte-G | 14 | $185 | $13 |
| Metronidazole | 28 | $179 | $6 |
| Amoxicillin-Clavulanate Potass | 16 | $173 | $11 |
| Ondansetron Odt | 12 | $136 | $11 |
| Procto-Med Hc | 13 | $100 | $8 |
Year by year
| 2024 | 1,974 | 670 | 0% (0) | 25% | $880,694 |
| 2023 | 1,776 | 581 | None | 27% | $739,078 |
| 2022 | 1,736 | 495 | 1% (11) | 29% | $729,110 |
| 2021 | 1,679 | 520 | None | 36% | $679,978 |
| 2020 | 1,540 | 417 | None | 33% | $572,933 |
| 2019 | 1,535 | 406 | 0% (0) | 36% | $549,280 |
| 2018 | 1,323 | 354 | 0% (0) | 43% | $610,528 |
| 2017 | 1,098 | 289 | 0% (0) | None | $624,193 |
| 2016 | 884 | 246 | 0% (0) | None | $469,186 |
| 2015 | 859 | 245 | None | 46% | $363,647 |
| 2014 | 589 | 184 | None | 55% | $173,747 |
| 2013 | 463 | 158 | None | 55% | $95,880 |
Part D prescriptions only. A drug prescribed to fewer than 11 people in a year is hidden.
See the drugs prescribed each year
2023: 26 drugs
| Creon | 70 | $185,736 | $2,653 |
| Linzess | 80 | $108,183 | $1,352 |
| Humira | 14 | $104,116 | $7,437 |
| Xifaxan | 40 | $104,064 | $2,602 |
| Mesalamine | 33 | $29,630 | $898 |
| Motegrity | 24 | $19,516 | $813 |
| Trulance | 15 | $16,431 | $1,095 |
| Colesevelam | 71 | $16,358 | $230 |
| Dexilant | 23 | $14,292 | $621 |
| Sod Sulf-Potass Sulf-Mag Sulf | 175 | $13,877 | $79 |
| Lubiprostone | 40 | $13,083 | $327 |
| Pantoprazole | 561 | $11,768 | $21 |
| Dexlansoprazole Dr | 19 | $9,283 | $489 |
| Sutab | 21 | $3,515 | $167 |
| Sucralfate | 41 | $2,546 | $62 |
| Suprep | 20 | $2,430 | $121 |
| Dicyclomine | 51 | $1,670 | $33 |
| Nortriptyline | 30 | $1,048 | $35 |
| Omeprazole | 65 | $890 | $14 |
| Scopolamine | 12 | $808 | $67 |
| Famotidine | 33 | $520 | $16 |
| Neomycin Sulfate | 12 | $440 | $37 |
| Gavilyte-G | 19 | $289 | $15 |
| Ondansetron | 18 | $267 | $15 |
| Amoxicillin-Clavulanate Potass | 17 | $208 | $12 |
| Metronidazole | 16 | $169 | $11 |
2022: 25 drugs
| Creon | 76 | $188,547 | $2,481 |
| Linzess | 82 | $108,736 | $1,326 |
| Xifaxan | 36 | $89,681 | $2,491 |
| Humira | 12 | $83,071 | $6,923 |
| Dexilant | 27 | $24,442 | $905 |
| Motegrity | 12 | $17,521 | $1,460 |
| Lubiprostone | 32 | $17,115 | $535 |
| Colesevelam | 68 | $14,187 | $209 |
| Sutab | 85 | $13,932 | $164 |
| Mesalamine | 26 | $13,392 | $515 |
| Pantoprazole | 572 | $11,626 | $20 |
| Sucralfate | 74 | $7,546 | $102 |
| Suprep | 49 | $5,593 | $114 |
| Prevalite | 23 | $3,966 | $172 |
| Ondansetron Odt | 17 | $2,237 | $132 |
| Dicyclomine | 51 | $1,554 | $30 |
| Sod Sulf-Potass Sulf-Mag Sulf | 16 | $1,220 | $76 |
| Nortriptyline | 48 | $967 | $20 |
| Omeprazole | 59 | $967 | $16 |
| Famotidine | 29 | $603 | $21 |
| Diphenoxylate-Atropine | 16 | $563 | $35 |
| Ondansetron | 33 | $530 | $16 |
| Metoclopramide | 18 | $212 | $12 |
| Tramadol | 11 | $154 | $14 |
| Amoxicillin-Clavulanate Potass | 12 | $130 | $11 |
2021: 24 drugs
| Creon | 111 | $217,263 | $1,957 |
| Xifaxan | 41 | $100,146 | $2,443 |
| Humira | 14 | $88,241 | $6,303 |
| Linzess | 59 | $57,442 | $974 |
| Dexilant | 38 | $31,336 | $825 |
| Mesalamine | 28 | $21,229 | $758 |
| Pentasa | 12 | $18,519 | $1,543 |
| Suprep | 131 | $14,517 | $111 |
| Pantoprazole | 500 | $11,787 | $24 |
| Sucralfate | 94 | $11,590 | $123 |
| Colesevelam | 55 | $10,672 | $194 |
| Lubiprostone | 21 | $10,314 | $491 |
| Clenpiq | 48 | $7,638 | $159 |
| Sutab | 45 | $7,040 | $156 |
| Prevalite | 19 | $3,390 | $178 |
| Dicyclomine | 45 | $1,992 | $44 |
| Ondansetron Odt | 30 | $1,631 | $54 |
| Omeprazole | 58 | $1,352 | $23 |
| Ondansetron | 41 | $1,076 | $26 |
| Nortriptyline | 36 | $577 | $16 |
| Famotidine | 15 | $334 | $22 |
| Metoclopramide | 23 | $183 | $8 |
| Amoxicillin-Clavulanate Potass | 11 | $114 | $10 |
| Amoxicillin | 14 | $92 | $7 |
2020: 24 drugs
| Creon | 101 | $199,256 | $1,973 |
| Xifaxan | 38 | $90,069 | $2,370 |
| Linzess | 42 | $44,712 | $1,065 |
| Dexilant | 55 | $31,933 | $581 |
| Amitiza | 41 | $23,629 | $576 |
| Mesalamine | 24 | $21,702 | $904 |
| Pentasa | 12 | $18,519 | $1,543 |
| Colesevelam | 70 | $16,807 | $240 |
| Suprep | 132 | $13,831 | $105 |
| Pantoprazole | 396 | $9,664 | $24 |
| Mesalamine Dr | 23 | $9,636 | $419 |
| Welchol | 12 | $7,985 | $665 |
| Sucralfate | 77 | $4,675 | $61 |
| Prevalite | 18 | $2,866 | $159 |
| Dicyclomine | 78 | $2,720 | $35 |
| Omeprazole | 68 | $1,245 | $18 |
| Ondansetron Odt | 36 | $1,074 | $30 |
| Nortriptyline | 35 | $541 | $15 |
| Ondansetron | 27 | $530 | $20 |
| Diphenoxylate-Atropine | 14 | $501 | $36 |
| Famotidine | 18 | $460 | $26 |
| Amoxicillin-Clavulanate Potass | 12 | $186 | $15 |
| Prednisone | 14 | $127 | $9 |
| Metoclopramide | 11 | $77 | $7 |
2019: 24 drugs
| Creon | 115 | $191,886 | $1,669 |
| Xifaxan | 30 | $68,109 | $2,270 |
| Relistor | 13 | $45,782 | $3,522 |
| Linzess | 27 | $30,833 | $1,142 |
| Dexilant | 41 | $28,173 | $687 |
| Mesalamine | 28 | $23,462 | $838 |
| Amitiza | 31 | $21,287 | $687 |
| Pentasa | 11 | $16,976 | $1,543 |
| Colesevelam | 66 | $16,679 | $253 |
| Welchol | 27 | $14,758 | $547 |
| Suprep | 140 | $13,930 | $99 |
| Budesonide Ec | 14 | $12,544 | $896 |
| Pantoprazole | 367 | $8,820 | $24 |
| Sucralfate | 104 | $2,590 | $25 |
| Prevalite | 12 | $1,834 | $153 |
| Omeprazole | 66 | $1,513 | $23 |
| Dicyclomine | 79 | $1,368 | $17 |
| Transderm-Scop | 13 | $1,006 | $77 |
| Scopolamine | 11 | $719 | $65 |
| Ranitidine | 17 | $690 | $41 |
| Ondansetron | 30 | $556 | $19 |
| Nortriptyline | 39 | $458 | $12 |
| Proctozone-Hc | 13 | $345 | $27 |
| Ondansetron Odt | 32 | $287 | $9 |
2018: 23 drugs
| Creon | 67 | $98,899 | $1,476 |
| Relistor | 22 | $74,393 | $3,381 |
| Xifaxan | 18 | $36,011 | $2,001 |
| Linzess | 34 | $35,983 | $1,058 |
| Amitiza | 51 | $35,231 | $691 |
| Dexilant | 53 | $29,218 | $551 |
| Welchol | 58 | $21,622 | $373 |
| Pentasa | 12 | $18,519 | $1,543 |
| Suprep | 121 | $11,439 | $95 |
| Delzicol | 13 | $7,443 | $573 |
| Pantoprazole | 307 | $5,864 | $19 |
| Colesevelam | 17 | $4,270 | $251 |
| Sucralfate | 69 | $2,088 | $30 |
| Prevalite | 14 | $1,660 | $119 |
| Transderm-Scop | 22 | $1,554 | $71 |
| Omeprazole | 65 | $1,158 | $18 |
| Dicyclomine | 76 | $899 | $12 |
| Ondansetron Odt | 19 | $759 | $40 |
| Ranitidine | 18 | $406 | $23 |
| Nortriptyline | 26 | $362 | $14 |
| Metronidazole | 12 | $197 | $16 |
| Prednisone | 11 | $141 | $13 |
| Metoclopramide | 19 | $89 | $5 |
2017: 25 drugs
| Creon | 43 | $57,368 | $1,334 |
| Relistor | 16 | $48,537 | $3,034 |
| Linzess | 54 | $45,276 | $838 |
| Xifaxan | 28 | $44,087 | $1,575 |
| Amitiza | 50 | $29,787 | $596 |
| Lialda | 13 | $23,133 | $1,779 |
| Dexilant | 37 | $22,196 | $600 |
| Welchol | 59 | $21,195 | $359 |
| Pentasa | 12 | $16,700 | $1,392 |
| Viread | 13 | $13,776 | $1,060 |
| Delzicol | 15 | $11,760 | $784 |
| Suprep | 61 | $5,351 | $88 |
| Pantoprazole | 216 | $4,140 | $19 |
| Esomeprazole Magnesium | 12 | $3,596 | $300 |
| Carafate | 12 | $2,241 | $187 |
| Sucralfate | 64 | $1,932 | $30 |
| Omeprazole | 75 | $1,355 | $18 |
| Misoprostol | 11 | $1,330 | $121 |
| Dicyclomine | 50 | $691 | $14 |
| Ondansetron Odt | 15 | $526 | $35 |
| Ranitidine | 16 | $390 | $24 |
| Nortriptyline | 21 | $282 | $13 |
| Metronidazole | 13 | $131 | $10 |
| Amoxicillin-Clavulanate Potass | 12 | $120 | $10 |
| Metoclopramide | 19 | $83 | $4 |
2016: 19 drugs
| Creon | 34 | $47,904 | $1,409 |
| Linzess | 39 | $30,573 | $784 |
| Amitiza | 56 | $28,349 | $506 |
| Lialda | 16 | $25,213 | $1,576 |
| Welchol | 62 | $23,311 | $376 |
| Asacol Hd | 13 | $18,554 | $1,427 |
| Dexilant | 32 | $18,449 | $577 |
| Pentasa | 12 | $15,335 | $1,278 |
| Viread | 12 | $11,991 | $999 |
| Delzicol | 13 | $7,178 | $552 |
| Carafate | 29 | $5,254 | $181 |
| Pantoprazole | 166 | $3,268 | $20 |
| Suprep | 36 | $2,976 | $83 |
| Omeprazole | 100 | $1,526 | $15 |
| Sucralfate | 34 | $1,040 | $31 |
| Ondansetron Odt | 12 | $308 | $26 |
| Dicyclomine | 19 | $244 | $13 |
| Ranitidine | 14 | $242 | $17 |
| Nortriptyline | 14 | $148 | $11 |
2015: 18 drugs
| Creon | 26 | $45,772 | $1,760 |
| Lialda | 18 | $33,587 | $1,866 |
| Amitiza | 61 | $24,114 | $395 |
| Welchol | 74 | $21,133 | $286 |
| Pentasa | 12 | $12,883 | $1,074 |
| Dexilant | 28 | $12,163 | $434 |
| Linzess | 22 | $11,758 | $534 |
| Carafate | 32 | $4,683 | $146 |
| Suprep | 34 | $2,728 | $80 |
| Omeprazole | 131 | $2,300 | $18 |
| Pantoprazole | 117 | $1,883 | $16 |
| Sucralfate | 30 | $1,303 | $43 |
| Hydrocortisone | 11 | $246 | $22 |
| Dicyclomine | 23 | $226 | $10 |
| Ondansetron Odt | 17 | $195 | $11 |
| Metoclopramide | 23 | $187 | $8 |
| Metronidazole | 13 | $181 | $14 |
| Ciprofloxacin | 16 | $137 | $9 |
2014: 16 drugs
| Lialda | 35 | $39,859 | $1,139 |
| Creon | 15 | $22,999 | $1,533 |
| Amitiza | 36 | $19,733 | $548 |
| Pentasa | 18 | $15,290 | $849 |
| Dexilant | 34 | $13,325 | $392 |
| Welchol | 53 | $13,035 | $246 |
| Linzess | 29 | $8,678 | $299 |
| Nexium | 16 | $8,502 | $531 |
| Carafate | 18 | $2,338 | $130 |
| Omeprazole | 81 | $1,889 | $23 |
| Misoprostol | 11 | $1,397 | $127 |
| Suprep | 13 | $1,032 | $79 |
| Pantoprazole | 50 | $946 | $19 |
| Sucralfate | 12 | $675 | $56 |
| Ondansetron Odt | 11 | $168 | $15 |
| Dicyclomine | 14 | $113 | $8 |
2013: 12 drugs
| Pentasa | 22 | $14,117 | $642 |
| Welchol | 58 | $12,261 | $211 |
| Nexium | 14 | $9,070 | $648 |
| Dexilant | 20 | $7,833 | $392 |
| Misoprostol | 15 | $1,720 | $115 |
| Omeprazole | 47 | $1,108 | $24 |
| Suprep | 12 | $892 | $74 |
| Pantoprazole | 20 | $698 | $35 |
| Sucralfate | 11 | $593 | $54 |
| Gavilyte-N | 23 | $440 | $19 |
| Peg-3350 With Flavor Packs | 24 | $423 | $18 |
| Dicyclomine | 11 | $123 | $11 |
Money from drug and device companies
$220 in 2025
| 2025 | 2 | 2 | None | $220 |
| 2023 | 1 | 4 | None | $317 |
| 2022 | 2 | 4 | None | $510 |
| 2021 | 3 | 7 | None | $744 |
| 2020 | 2 | 4 | None | $60 |
| 2019 | 1 | 2 | None | $28 |
Paid work is consulting, speaking, honoraria and royalties, as opposed to meals and travel.
A payment is not proof that care is biased.
| Boston Scientific | Axios | $126 | 1 payment
|
| Fujifilm Healthcare Americas | Fujifilm | $94 | 1 payment
|
See all 2 published payments
| Fujifilm Healthcare Americas | Meals · 2025-06-23 | Fujifilm | $94 |
| Boston Scientific | Meals · 2025-04-16 | Axios | $126 |
See earlier years (2023, 2022, 2021, 2020, 2019)
2023: $317
| Creo Medical | Speedboat | $317 | 4 payments
|
2022: $510
| Creo Medical | Speedboat | $498 | 2 payments
|
| Abbvie | Linzess | $13 | 1 payment
|
2021: $744
| Creo Medical | Creo Medical | $707 | 1 payment
|
| AbbVie | Mavyret | $25 | 1 payment
|
| Nestle HealthCare Nutrition | Zenpep | $13 | 1 payment
|
2020: $60
| AbbVie | Humira | $38 | 2 payments
|
| Supernus Pharmaceuticals | Oxtellar Xr | $23 | 2 payments
|
2019: $28
| Salix Pharmaceuticals a division of Bausch Health US | Xifaxan | $28 | 2 payments
|
Professional record
- NPI
- 1396864872
- Licence
- CA A102814California A102814: Current · expires 2027-06-30
- Trained
- Vanderbilt University School of Medicine, 2005
- Group
- Stanford Health Care
- Video visits
- Lists video visits
- Gender
- Male
More record details
- Sole proprietor
- No
- Taxonomy
- Federal specialty code 207RG0100X (207RG0100X)
- Mailing address
- 5565 W Las Positas Blvd Ste 200, Pleasanton, CA, 94588
- NPI first listed
- 2007-03-28
- NPI last updated
- 2024-04-12
- NPI record certified
- 2024-04-12
This is when the NPI record was last certified, not a medical board exam.
Extra NPI addresses: 5575 W Las Positas Blvd Ste 130, Pleasanton, CA, 94588